Research Article

Ubenimex Reverses MDR in Gastric Cancer Cells by Activating Caspase-3-Mediated Apoptosis and Suppressing the Expression of Membrane Transport Proteins

Qie Guo,1 Fan-jing Jing,2 Hai-jun Qu,1 Wen Xu,1 Bing Han,1 Xiao-min Xing,1 Hong-yan Ji,1 and Fan-Bo Jing1

1Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266003, China
2Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266003, China

Correspondence should be addressed to Fan-Bo Jing; jingbf178@sina.com

Received 12 September 2018; Revised 9 December 2018; Accepted 27 December 2018; Published 20 February 2019

Academic Editor: Stephen H. Safe

Copyright © 2019 Qie Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gastric cancer (GC) is one of the most malignant tumors, accounting for 10% of deaths caused by all cancers. Chemotherapy is often necessary for treatment of GC; the FOLFOX regimen is extensively applied. However, multidrug resistance (MDR) of GC cells prevents wider application of this treatment. Ubenimex, an inhibitor of CD13, is used as an immune adjuvant to treat hematological malignancies. Here, we demonstrate that CD13 expression positively correlates with MDR development in GC cells. Moreover, Ubenimex reverses the MDR of SGC7901/X and MKN45/X cells and enhances their sensitivity to FOLFOX, in part by decreasing CD13 expression, which is accompanied by downregulation of Bcl-xl, Bcl-2, and survivin expression; increased expression of Bax; and activation of the caspase-3-mediated apoptotic cascade. In addition, Ubenimex downregulates expression of membrane transport proteins, such as P-gp and MRP1, by inhibiting phosphorylation in the PI3K/AKT/mTOR pathway to increase intracellular accumulations of 5-fluorouracil and oxaliplatin, a process for which downregulation of CD13 expression is essential. Therefore, the present results reveal a previously uncharacterized function of CD13 in promoting MDR development in GC cells and suggest that Ubenimex is a candidate for reversing the MDR of GC cells.

1. Introduction

Gastric cancer (GC) is the fourth most serious cancer worldwide, and the second greatest cause of cancer-related death, next to lung cancer [1]. Surgery is the main treatment for GC, but late diagnoses are associated with advanced cancers, which tend to be metastatic after resection [2].Chemotherapy, often utilized to treat GC, offers better outcomes than surgery alone [3]. Combined treatment of 5-fluorouracil and its derivatives, including paclitaxel and platinum compounds, is the first-line chemotherapy for GC. Among these, the FOLFOX regimen, comprised of 5-fluorouracil, oxaliplatin, and leucovorin, is often the primary choice of chemotherapy for GC due to its mild toxicity and better tolerance; it improves the median survival of patients, especially those with advanced GC [4–6]. However, application of the FOLFOX regimen for GC patients is hindered by multidrug resistance (MDR), for which tumor cells not only show resistance to a specific drug, but also are resistant to other drugs with different structures and mechanisms [7].

Apoptosis resistance, which contributes to the MDR in GC cells, is mainly manifested as the aberrant decrease of proapoptotic genes or overexpression of antiapoptotic proteins [8]. In GC cells, dysregulated expression of the B-cell lymphoma 2 (Bcl-2) family, including Bcl-2, Bcl-xl, and Bad, and inhibitor of apoptosis proteins (IAPs), represented as X-linked inhibitor of apoptosis protein (XIAP), livin, and survivin, followed by inactivation of the caspase-3 or caspase-8 pathway, are the main causes of apoptosis resistance induced by chemotherapeutic drugs [9–11].

Drug efflux, facilitated by membrane transport proteins, is associated with the development of MDR in GC cells [12]. Membrane transport proteins represented by the ATP-binding cassette (ABC) transport superfamily, including
P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP/ABCG), pump out a variety of chemotherapeutic drugs to increase drug efflux and reduce intracellular concentrations, thereby inducing drug resistance in tumor cells [13]. Expression of the MDRI gene encoding P-gp is upregulated in the chemoresistant GC cell line, SCG-7901/ADR, compared to that in parental SCG-7901 cells [14]. In addition, increased invasive depth and numbers of metastatic lymph nodes in GC specimens are tied to elevated expression of P-gp [15]. Further, after radical gastrectomy, MRP1 expression is used to guide selection of chemotherapeutic regimens, consistent with the positive association between MRP1 expression and drug susceptibility [16]. Protein levels of LRP are higher in GCs with high differentiation, compared to mucinous carcinomas with poorly differentiated cells, suggesting that LRP is necessary for development of MDR in GC cells. Moreover, LRP is aberrantly expressed in GC patients with chemotherapy treatment rather than in those without administration of chemotherapeutic drugs, suggesting that, in GC cells, it is involved in the formation of intrinsic chemoresistance [17].

In tumor cells, signaling pathways regulating cell proliferation are related to the development of MDR. In particular, aberrant activation of the phosphoinositol 3-kinase/protein kinase B (PI3K/AKT) pathway promotes the development of chemoresistance in a variety of tumor cells, including GC cells [18] by phosphorylating substrates via tyrosine kinase receptors, such as mTOR, GSK-3β, and JNK [19]. Overactivation of the PI3K/AKT pathway in the gemcitabine-resistant ovarian cancer cell line, A2870CP, suppresses expression of AKT-inhibited apoptosis signal-regulating kinase 1 (ASK1), resulting in the reduced expression of downstream JNK and p38 to induce MDR [20]. Drug resistance to adriamycin, paclitaxel, and 5-fluorouracil mediated by the Ras protein in the breast cancer cell line, MCF-7, is related to the increased activity of p-PI3K and p-AKT [21]. In K562 cells, resveratrol inhibits the PI3K/AKT pathway to reduce the expression of P-gp and BCRP2 and reverses MDR [22]. However, how the PI3K/AKT pathway causes MDR in GC cells is unclear.

CD13, also called aminopeptidase N (APN), is a transmembrane glycoprotein with metalloproteinase activity; it is involved in tumor angiogenesis and adhesion [23]. Ubenimex, the only CD13 inhibitor available, has been used as an immunomodulating adjuvant for treating hematological malignancies; it enhances the killing activity of T- or B-lymphocytes and natural killer cells, but this effect is not related to the regulation of CD13 activity or expression [24, 25]. The application of Ubenimex for treatment of GC has not been reported.

Herein, our findings showed that, for GC cells, there was a positive correlation between CD13 expression and MDR. Furthermore, Ubenimex reversed MDR in SGC7901/X and MKN45/X cells and enhanced cell sensitivity to the FOLFOX regimen via inhibiting CD13 expression. Ubenimex-dependent ablation of CD13 downregulated expression of antiapoptotic proteins, including Bcl-xl, Bcl-2, and survivin, and upregulated expression of the proapoptotic protein, Bax. Accordingly, in MDR GC cells, Ubenimex activated the caspase-3-mediated cascade to promote FOLFOX-induced apoptosis. In addition, via decreasing CD13 expression, Ubenimex inhibited phosphorylation of the PI3K/AKT/mTOR pathway to downregulate P-gp and MRP1 expression, thus increasing intracellular accumulation of 5-fluorouracil and oxaliplatin in MDR GC cells. Our findings suggest that Ubenimex provides a new strategy for the treatment of chemoresistant GC.

2. Materials and Methods

2.1. Cell Culture. The human GC cell line SGC7901 was purchased from the American Type Culture Collection (ATCC), and MKN45 cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Peripheral blood mononuclear cells (PBMCs) were isolated by ficoll-hypaque density gradient centrifugation (Amersham Pharmacia Biotech) of heparinized venous blood obtained from healthy volunteer donors at the Affiliated Hospital of Qingdao University (Qingdao, China), under the National Regulation of Clinical Sampling in China. Cells were maintained in RPMI 1640 culture medium (GIBCO/BRL) supplemented with 10% heat-inactivated FBS at 37°C in a humidified atmosphere with 5% CO2.

2.2. Reagents. Ubenimex was purchased from Shenzhen Main Luck Pharmaceutical, Inc. (Shenzhen, China). 5-Fluorouracil and leucovorin were purchased from Xudong Haipu Pharmaceutical Co., Ltd. (Shanghai, China). Cisplatin and oxaliplatin were obtained from Qilu Pharmaceutical Co., Ltd. (Jinan, China). Rabbit anti-human antibodies against P-gp, MRP1, ABCG2, LRP, PI3K(P85), p-PI3K(p-P85), AKT, p-AKT, GSK-3β, p-GSK-3β, JNK, p-JNK, mTOR, p-mTOR, and PE-conjugated AffiniPure goat anti-rabbit IgG (H+L) were acquired from Santa Cruz Biotechnology (Chicago, USA). Rabbit anti-human antibodies against P-gp, MRPI, ABCG2, LRP, PI3K(P85), p-PI3K(p-P85), AKT, p-AKT, GSK-3β, p-GSK-3β, JNK, p-JNK, mTOR, p-mTOR, and PE-conjugated cytchrome c (Cyto-C) mAb were obtained from Cell Signaling Technology (Danvers, MA).

2.3. Tissue Specimens. Normal stomach tissues (nonneoplastic disease) and tissue samples from GC patients (45 males and 75 females, age range 35–78) were obtained from the Affiliated Hospital of Qingdao University (Qingdao, China) under the National Regulation of Clinical Sampling in China. These gastric surgical specimens were classified according to the receipt of chemotherapy (n=65 receiving chemotherapy with the FOLFOX regimen; n=55 without receiving chemotherapy). All tissue specimens were preserved in liquid nitrogen for western blot analysis or postfixed with neutral formaldehyde solution followed by paraffin embedding for immunohistochemical staining. This study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University. All animal experiments were performed in accordance with the guidelines of the Chinese Academy of Sciences (Shanghai, China). Peripheral blood mononuclear cells (PBMCs) were isolated by ficoll-hypaque density gradient centrifugation (Amersham Pharmacia Biotech) of heparinized venous blood obtained from healthy volunteers donors at the Affiliated Hospital of Qingdao University (Qingdao, China), under the National Regulation of Clinical Sampling in China. Cells were maintained in RPMI 1640 culture medium (GIBCO/BRL) supplemented with 10% heat-inactivated FBS at 37°C in a humidified atmosphere with 5% CO2.
University, and informed written consent was obtained from each patient.

2.4. Establishment of Human MDR GC Cell Lines. SGC7901 and MKN45 cells in the logarithmic growth phase were seeded in cell culture at a concentration of 1 × 10^5 cells/mL. Once cells had adhered and grown to approximately 70–90% confluency, a culture medium containing 5-fluorouracil (2 μg/mL) or oxaliplatin (0.1 μg/mL) was added. 12 hours later, cell debris was discarded, and surviving cells (1 × 10^5/mL) were treated with drug-free culture medium. After cells grew to 70–80% confluence, drug-containing culture medium with the same concentration was added repeatedly. The above steps were repeated over seven months until induction of MDR in cells (designated SGC7901/X and MKN45/X) was confirmed.

2.5. Construction of pTZU-CD13-shRNA and pEGFP-N1-CD13 Plasmid. siRNA duplexes consisting of a base sequence targeting human CD13 mRNA and loop base rings were designed using BLOCK-iT RNAi Designer. Single-stranded oligodeoxynucleotides (ODNs) were synthesized with BamHI and EcoRI overhanging ends by Sangon Biotech Co., Ltd. (Shanghai, China). The shRNA template sequences are shown in Supplementary Table S1. Annealed top and bottom ODNs were mixed and then placed in a PCR instrument to synthesize shRNA templates at 95°C for 30 s, 72°C for 2 min, 37°C for 2 min, and 25°C for 2 min.

The pTZU6+1 plasmid was digested with BamHI and HindIII restriction enzymes and recovered by 0.8% agarose gel electrophoresis. shRNA templates were reacted with pTZU6+1 plasmid via T4 NDA ligase. The pTZU-shRNAs were transformed into DH5αa Escherichia coli, and all clones were sent for sequencing to confirm correct insertion of the target sequence.

For construction of the overexpression plasmid, pEGFP-N1-CD13, we searched for the coding sequence of human CD13 in Genbank and designed PCR primers with SacI and AgeI overhangs. The coding sequence of CD13 is presented in Supplementary Table S2. CD13 cDNAs from PBMCs were amplified by PCR. Construction of the overexpression plasmid, pEGFP-N1-CD13, was performed according to methods previously described [26].

These plasmids were transfected into cells for 24 h using Lipofectamine™ 3000 Transfection Reagent (Invitrogen) according to the manufacturer’s instructions.

2.6. Evaluation of Drug Resistance. MDR GC cells were treated with pTZU-CD13-shRNA or the combination of Ubenimex (400 μmol/L) and pEGFP-N1-CD13 for 24 h. Then, MDR GC cells and their parental cells were treated with culture medium containing various concentrations of 5-fluorouracil (200, 100, 50, 25, 12.5, and 6.25 μg/mL), or cisplatin or oxaliplatin (0.4, 0.8, 1.6, 3.2, 6.4, and 12.8 μg/mL). After 48 hours, the cells were cultured in drug-free medium (100 μL) and Cell Counting Kit-8 (CCK-8) (10 μL) for another 4 h. Absorbance of cells at 450 nm was read by a microplate reader (Bio-Rad, USA). IC50 values, also known as half-maximal inhibitory concentrations, and resistance indices (RIs) were calculated according to previously described equations [26].

2.7. Cell Sensitivity Assays. MDR GC cells were treated or untreated with Ubenimex (400 μmol/L) and/or indicated plasmids for 24 h. Then they were collected and seeded into 96-well culture plates at a concentration of 1 × 10^4 cells/mL. After the cells were attached to the plate walls, they were incubated with the FOLFOX regimen, containing 5-fluorouracil (10 μmol/L), oxaliplatin (5 μmol/L), and leucovorin (5 μmol/L), followed by incubation for 0–72 h. Finally, CCK-8 reagent (10 μL) was added for another 2 h of incubation, and absorbance of cells at 450 nm was read. Growth curves were drawn to assess cell sensitivity towards the FOLFOX regimen.

2.8. Immunohistochemistry Assays. Tissue specimens were serially sectioned at 4-μm thickness and fixed in Bouin's solution for 10 min; subsequently, they were blocked in calf serum (20 g/L) for 1 h. The sections were stained with a primary antibody against CD13 at a dilution of 1:500, followed by incubation with HRP-conjugated secondary antibody (1:100 dilution) for 1 h at room temperature. Finally, these tissue sections were incubated in diaminobenzidine solution at 37°C for 15 min, followed by redyeing, dehydration, xylene dispersion, and slide mounting; they were then observed under a light microscope. Image-Pro Plus V6.0 software was used for image analysis. Brown or brownish-yellow particles were considered positive, and scores were obtained according to the percentage of colored particles per field of view. A score of 0 represented <5% positive staining (negative, −); a score of 1 represented 5–15% positive staining (weak positive, +); a score of 2 represented 15–40% positive staining (moderate positive, ++); a score of 3 represented 40–65% positive staining; and a score of 4 represented >65% positive staining. Scores of 3 and higher were considered strong positive (+++).

2.9. Western Blot Analysis. Cell or tissue lysates were prepared using a total protein extraction reagent (Proteintech). The protein samples were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Millipore). The membranes were blocked in Tris-buffered saline with 5% (w/v) nonfat dry milk and then incubated with primary antibodies overnight at 4°C, followed by exposure to HRP-conjugated secondary antibody for 1 hour at room temperature. Immunoreactive proteins were visualized by the ChemiDoc™ XRS+ System (Bio-Rad).

2.10. Accumulation of Chemotherapeutic Drugs. MDR GC cells were treated with Ubenimex and the pEGFP-N1-CD13 plasmid for 24 h and then were exposed to FOLFOX for another 6 h. Cells were suspended in ice-cold PBS, followed by lysis buffer (300 μL) (Beyotime). After incubation at 37°C for 5 min, the intracellular accumulations of 5-fluorouracil,
Table 1: The CD13 expression and the clinicopathological features of GC patients.

| Clinicopathological features | CD13 expression | PR(%) | P value |
|------------------------------|-----------------|-------|---------|
| Age                          |                 |       |         |
| ≤50 years                    | N  55           | 18    | 15      | 15  7 | 67.2 | 0.76² |
| >50 years                    | N  65           | 19    | 10      | 23  13 | 70.7 |       |
| Gender                       |                 |       |         |
| Male                         | N  56           | 20    | 15      | 15  12 | 73.3 | 0.67² |
| Female                       | N  64           | 17    | 10      | 23  8  | 67.3 |       |
| Tumor Differentiation        |                 |       |         |
| Well                         | N  46           | 17    | 10      | 11  8  | 65.6 | 0.64² |
| Moderately                   | N  36           | 9     | 8       | 14  5  | 75.6 |       |
| Poor                         | N  38           | 11    | 7       | 13  7  | 71.0 |       |
| Tumor Location               |                 |       |         |
| Proximal                     | N  51           | 14    | 12      | 16  9  | 72.5 | 0.53² |
| Distal                       | N  69           | 23    | 13      | 22  11 | 66.7 |       |
| Clinical stages              |                 |       |         |
| T1-T2                        | N  63           | 17    | 12      | 26  8  | 71.4 | 0.46² |
| T3-T4                        | N  57           | 20    | 13      | 12  12 | 64.6 |       |
| Nodal Metastasis             |                 |       |         |
| N₀                           | N  62           | 12    | 14      | 20  16 | 80.8 | 0.013**|
| N₁-N₃                       | N  58           | 25    | 11      | 18  4  | 56.9 |       |
| Application of FOLFOX        |                 |       |         |
| Yes                          | N  65           | 9     | 6       | 31  19 | 86.1 | 0.009**|
| No                           | N  55           | 28    | 19      | 7   1  | 49.0 |       |

PR(%): positive rate. 
χ² test was adopted to evaluate association between the clinical parameters with CD13 expression in GC patients. *P < 0.05, **P < 0.01, and #P > 0.05.

oxaliplatin, and leucovorin were determined by LC-MS/MS (Agilent Technologies, US).

2.11. Immunoprecipitation Assays. MDR GC cells were treated with Ubenimex (400 μmol/L) for 24 h and were harvested and lysed on ice. Then, cell supernatant (20 μL) was incubated with G-Sepharose at room temperature for 2 h. The mixture was centrifuged to precipitate the agarose beads, which were washed with lysis buffer. Beads were mixed with 1× loading buffer (20 μL), followed by heating at 100°C for 5 min to collect the supernatant. Western blot assays were used to determine whether proteins in the supernatant coprecipitated with mTOR.

2.12. Release and Detection of Cyto-C. MDR GC cells were treated with a combination of Ubenimex and the pEGFP-N1-CD13 plasmid for 24 h and then exposed to FOLFOX. At 24 or 48 h later, cells were collected and suspended in Hanks solution (Sigma-Aldrich), followed by incubation with fluorescent-labeled Cyto-C antibodies (2 μL) at 4°C for 1 h. All stained cells were analyzed with a flow cytometer, and the data were processed with WinMDI 2.9 software (Scripps Research Institute, La Jolla, CA).

2.13. Apoptosis Detection by the TUNEL Method. MDR GC cells were treated with Ubenimex in the presence or absence of the pEGFP-N1-CD13 plasmid for 24 h and were treated with FOLFOX for another 24 or 48 h. Collected cells were fixed with 4% paraformaldehyde for 1 h. These cells were washed and incubated with 0.1% Triton X-100 on ice for 2 min, followed by TUNEL assay reagent (20 μL) at 37°C for 60 min. As observed under a fluorescent microscope, the percentage of apoptotic cells staining with red fluorescence was quantified by Image-Pro Plus V6.0 software.

2.14. Statistical Analyses. Statistical analyses were performed with the paired Student t-test (two samples) and one-way ANOVA (multiple comparisons). Data were analyzed by SPSS 18.0 (SPSS, Chicago, IL, USA). Experiments were repeated three or more times, and test results were expressed as means ± SD, *P values < 0.05 or **P values < 0.01 were considered to be significant.

3. Results

3.1. CD13 Expression Positively Correlates with MDR Formation in GC Cells. CD13 is upregulated in GCs [27]; however, an association between CD13 expression and chemoresistance of GC cells has not been shown. In this study, immunohistochemistry results demonstrated that various grades of expression of CD13 were present in tissue samples from the 120 GC patients (Table 1). Furthermore, CD13 expression in GCs of patients after chemotherapy was elevated relative to
Figure 1: CD13 is an inducer to promote the MDR development of GC cells. (a) CD13 expression in typical tissue sections from advanced GC patients with or without chemotherapy treatment, was determined by immunohistochemistry analysis. Intuitive expression of CD13 was shown as brown or brownish-yellow particles. Normal gastric mucosa tissues were used as the normal controls. (b) Comparison of CD13 protein levels between non-chemotherapy and chemotherapy group in GC patients was carried out by western blotting analysis. The expression levels of CD13 were normalized to those of -actin, the horizontal line represents the median value, and the error bars indicate the SEM. **P<0.01. (c) The protein expression of LRP, P-gp, MRP1, and ABCG2 in parental cells and MDR GC cells was determined by western blotting analysis. Data are shown as representatives (left panels) and relative densities compared to β-actin from three independent experiments with means ± SD (right panels). **P<0.01. (d) The expression of CD13 in parental cells and MDR GC cells was determined by western blotting analysis. Data are shown as representatives (upper panels) and relative gray values contrasted with β-actin from three independent experiments with means ± SD (bottom panels). **P<0.01.

that in patients who received no chemotherapy (Figure 1(a)). These findings were verified by western blotting (Figure 1(b)).

To determine if high expression of CD13 is associated with MDR in GC cells, we applied increasing concentrations of oxaliplatin and 5-fluorouracil to acquire the human MDR GC cell lines, SGC7901/X and MKN45/X. To assess the MDR of GC cells, we used the CCK-8 method to derive the IC50 values and RIs for SGC7901/X cells towards 5-fluorouracil, cisplatin, and oxaliplatin. The IC50 values for SGC7901/X and MKN45/X cells were higher relative to the parental cells, with corresponding RIs ranging from 8.34 to 20.81 and 6.26 to 21.65, respectively (Supplementary Table S3). The protein expressions of LRP, P-gp, MRPI, and ABCG2 were also upregulated in MDR GC cells (Figure 1(c)), suggesting that SGC7901/X and MKN45/X cells had acquired stable drug resistance. Moreover, western blotting assays showed that SGC7901/X and MKN45/X cells had a greater abundance of CD13 protein than their parental cells (Figure 1(d)). To examine the relationship between CD13 expression and the MDR of GC cells, we constructed the pTZU-CD13-shRNA plasmid to silence CD13 mRNA and assessed its effects on drug sensitivity of MDR GC cells. Application of the pTZU-CD13-shRNA plasmid reduced the IC50 values and RIs for SGC7901/X and MKN45/X cells treated with chemotherapeutic drugs (Tables 2 and 3). These results suggested that in GC cells CD13 participates in the development of MDR.

3.2. Ubenimex Reverses MDR of GC Cells by Decreasing CD13 Expression. As an inhibitor of CD13, Ubenimex induces immune activation by stimulating CD3+CD4+ T lymphocytes and CD16+CD56+ NK cells [28]. However, there is no report on the application of Ubenimex for the treatment
versus 5-fluorouracil, cisplatin, and oxaliplatin without pTZU-CD13-shRNA transfection. In this hypothesis, Ubenimex suppressed CD13 expression in GC cells via targeting CD13 expression. In line with findings, we speculated that Ubenimex exerts its function after CD13 was overexpressed, did not make MDR GC cells insensitive to FOLFOX (Figures 2(a) and 2(b)). Based on these findings, we speculated that Ubenimex exerts its function on GC cells via targeting CD13 expression. In line with this hypothesis, Ubenimex suppressed CD13 expression in SGC7901/X and MKN45/X cells (Figure 2(c)). Therefore, Ubenimex may be a promising agent for reversing MDR in GC cells and for enhancing their chemosensitivity to the FOLFOX regimen, for which ablation of CD13 expression is essential.

3.3. Downregulation of CD13 Expression by Ubenimex Promotes FOLFOX-Induced Apoptosis in GC Cells. To investigate the mechanism by which Ubenimex reverses the MDR of GC cells, we evaluated its effect on drug-induced tumor cell apoptosis. TUNEL staining demonstrated that Ubenimex promoted FOLFOX-induced apoptosis in SGC7901/X and

| Drugs  | SGC7901 IC50 (ug/ml) | SGC7901/X + pTZU6+1 IC50 (ug/ml) | SGC7901/X + pTZU-CD13-shRNA IC50 (ug/ml) |
|--------|----------------------|----------------------------------|-------------------------------------|
| 5-fluorouracil | 22.6±0.1            | 188.1±0.3                        | 8.3±0.3                             |
| Cisplatin       | 1.25±0.01           | 20.1±0.2                         | 18.8±0.1                            |
| Oxaliplatin     | 0.42±0.02           | 8.5±0.1                          | 21.3±0.2                            |

IC50 values and RIs were determined by the CCK-8 method. Data are expressed as means ± SD from three independent experiments. **P<0.01 versus 5-fluorouracil, cisplatin, and oxaliplatin without pTZU-CD13-shRNA transfection.

| Drugs  | SGC7901/X IC50 (ug/ml) | SGC7901/X + Ubenimex IC50 (ug/ml) | SGC7901/X + Ubenimex/pEGFP-N1-CD13 IC50 (ug/ml) |
|--------|-----------------------|-----------------------------------|-----------------------------------------------|
| 5-fluorouracil | 189.1±0.1            | 68.4±0.3**                        | 3.1±0.2**                                     |
| Cisplatin       | 21.1±0.2             | 17.8±0.1                          | 7.4±0.2**                                     |
| Oxaliplatin     | 8.4±0.1              | 20.4±0.1                          | 7.2±0.1**                                     |

IC50 values and RIs were determined by the CCK-8 method. Data are expressed as means ± SD from three independent experiments. **P<0.01 versus 5-fluorouracil, cisplatin, and oxaliplatin without Ubenimex. *P>0.05 versus 5-fluorouracil, oxaliplatin, and cisplatin with the pEGFP-N1-CD13 plasmid stimulation.

| Drugs  | MKN45 IC50 (ug/ml) | MKN45/X + pTZU6+1 IC50 (ug/ml) | MKN45/X + pTZU-CD13-shRNA IC50 (ug/ml) |
|--------|--------------------|---------------------------------|---------------------------------------|
| 5-fluorouracil | 20.54±0.02         | 147.9±0.02                      | 7.2±0.01                             |
| Cisplatin       | 0.41±0.01          | 8.3±0.02                        | 20.0±0.02                            |
| Oxaliplatin     | 18.9±0.01          | 125.7±0.01                      | 6.6±0.01                             |

IC50 values and RIs were determined by the CCK-8 method. Data are expressed as means ± SD from three independent experiments. *P<0.05 and **P<0.01 versus 5-fluorouracil, cisplatin, and oxaliplatin without pTZU-CD13-shRNA transfection.
Figure 2: Ubenimex overcomes MDR and increases the chemosensitivity of GC cells to FOLFOX by downregulating CD13 expression. ((a) and (b)) Indicated cells were incubated in the presence or absence of Ubenimex (400 μmol/l) for 24h, followed by FOLFOX, comprised of 5-fluorouracil (10 μmol/l), oxaliplatin (5 μmol/l), and leucovorin (5 μmol/l). Cell viability which can be the reflection of chemosensitivity for SGC7901/X (a) or MKN45/X (b) cells to FOLFOX was carried out by CCK-8 method as described previously. The results are expressed as the means ± SD of three replicates. **P < 0.01. (c) The expression of CD13 in SGC7901/X and MKN45/X cells with or without Ubenimex (400 μmol/l) treatment was confirmed by western blotting analysis. Data are demonstrated as representatives (upper panels) and relative gray values contrasted with β-actin from three independent experiments with means ± SD (bottom panels). **P<0.01.

MKN45/X cells in a time-dependent manner; however, this effect of Ubenimex was not evident in SGC7901/X cells after transfection with the pEGFP-N1-CD13 plasmid (Figures 3(a) and 3(b)).

We assessed the effects of Ubenimex on the expression of apoptosis-related proteins. Ubenimex reversed the elevated expression of Bcl-2, Bcl-xl, and survivin, but upregulated Bax expression in SGC7901/X cells, relative to their parental cells. However, the effects of Ubenimex towards apoptosis-related proteins were reversed after overexpression of CD13 (Figure 3(c)). Similar results were obtained for MKN45/X cells (Figure 3(d)). Cyto-C, a proapoptotic member of the Bcl-2 family, is present in the cytosol and in mitochondria [29]. After Ubenimex exposure, the release of Cyto-C was elevated in FOLFOX-treated SGC7901/X and MKN45/X cells, but the effects were largely reversed by overexpression of CD13 (Figures 3(e) and 3(f)). The activity of IAPs is blocked by second mitochondrial activator of caspase (Smac) but stimulated by proapoptotic factors; furthermore, activation of caspases is a final step in triggering apoptosis [30]. Our findings showed that, in FOLFOX-treated MDR GC cells treated with Ubenimex, the expressions of Smac and
Figure 3: Continued.
accumulation, but the concentrations of leucovorin were not changed appreciably (Figures 4(c) and 4(d)). However, downregulation of P-gp and MRP1 expression and the higher intracellular concentrations of chemotherapeutic drugs were reduced by transfection of the pEGFP-N1-C1D3 plasmid (Figure 4). These results suggest that Ubenimex inhibits the expression of MDR-associated proteins, including P-gp and MRP1, to increase drug accumulation in GC cells, for which low expression of CD13 is required.

3.4. Reduced Expression of CD13 Mediated by Ubenimex Lowers the Protein Levels of P-gp and MRP1 in GC Cells. A previous study showed that, for patients with advanced GC, the expressions of P-gp and MRP1 are higher in drug-resistant groups, compared with drug-sensitive groups [31]. Although there is no appreciable expression of P-gp and MRP1 in the mitoxantrone-induced resistant GC cell line EPG85-257, ABCG2 is aberrantly expressed relative to that in parental cells [32]. These results indicate that differential expressions of membrane transport proteins are associated with MDR and chemosensitivity of GC cells. Consistent with these results, for MDR GC cells, Ubenimex facilitates apoptosis in response to chemotherapeutic drugs. Particularly, regulation of aberrant expression of P-gp and MRP1, to increase drug accumulation in GC cells, for which low expression of CD13 is required.

Figure 3: Ubenimex regulates the expression of apoptosis-related proteins to promote FOLFOX-induced apoptosis in GC cells by suppressing CD13 expression. ((a) and (b)) Indicted cells were pretransfected with pEGFP-N1-C1D3 and then treated with Ubenimex; evaluation of FOLFOX-induced apoptotic SGC7901/X (a) and MKN45/X (b) cells was confirmed by TUNEL staining of red fluorescent (upper panels); the proportion of apoptotic cells was also shown as means ± SD from three independent experiments (bottom panels). *P < 0.05 and **P < 0.01. ((c) and (d)) Expressions of CD13 and apoptosis-related proteins in SGC7901/X (c) and MKN45/X (d) cells were determined via western blotting analysis. Data are also shown as representatives (left panels) and mean ± SD gray values normalized to β-actin expression from three independent experiments (right panels). **P < 0.01 and ***P > 0.05. (e) and (f)) Release concentration of Cyto-C in the culture supernatant of FOLFOX-treated SGC7901/X (e) and MKN45/X (f) cells with the treatment of Ubenimex or pEGFP-N1-C1D3 plasmid, was measured by flow cytometric analysis (left panels). Data are also expressed as means ± SD of positive cell numbers from three independent experiments (right panels). **P < 0.01. (g) and (h)) Indicated cells were treated with the combination of Ubenimex and pEGFP-N1-C1D3 plasmid for 24h and then stimulated with FOLFOX regimen for another 24h. Protein levels of Smac, total caspase-3 and caspase-8, or cleaved caspase-3 and cleaved caspase-8 in SGC7901/X (g) and MKN45/X (h) cells were detected by western blotting analysis. Data are shown as representatives (left panels) or means ± SD from three independent experiments (right panels). **P < 0.01 and ***P > 0.05.
Figure 4: Ubenimex suppresses the expression of membrane transport proteins by inhibiting CD3 expression to enhance drug accumulation in GC cells. ((a) and (b)) Indicted cells were pretreated with or without pEGFP-N1-CD13 plasmid and then stimulated with Ubenimex. The expressions of P-gp, MRP1, LRP, and ABCG2 SGC7901/X (a) and MKN45/X (b) cells were determined via western blotting analysis. Representative results are shown (left panels) and the means ± SD are revealed (right panels). *P < 0.05, **P < 0.01, and #P > 0.05. ((c) and (d)) Effect of Ubenimex (400 μmol/l) in the presence or absence of pEGFP-N1-CD13 plasmid on intracellular accumulation of 5-fluorouracil, oxaliplatin, and leucovorin in SGC7901/X cells (c) and MKN45/X (d) cells was evaluated via LC-MS/MS analysis. Data are expressed as means ±SD of three independent experiments. **P < 0.01 and #P > 0.05.

Notably, activation of the AKT/Gsk-3β/β-catenin pathway may contribute to gemcitabine resistance of human pancreatic cancer cells, in which the MDR1 gene acts downstream of β-catenin, and P-gp expression is upregulated [34, 35]. Hence, we hypothesized that, like Gsk-3β, mTOR relates to the expression of MDR-associated proteins. Immunoprecipitation experiments confirmed that, after exposure of MDR GC cells to Ubenimex, the mTOR and MRP1 proteins colocalized to the cytoplasm (Figure 5(c)); furthermore, in Ubenimex-treated SGC7901/X and MKN45/X cells, mTOR bound to P-gp (Figure 5(d)). These results indicated that, via a direct interaction, Ubenimex inhibits activation of the PI3K/AKT/mTOR pathway to downregulate expression of P-gp and MRP1.

4. Discussion

GC is a common cancer with a high incidence and mortality [32]. Due to late diagnoses, resection is often a temporary treatment; instead, combinations of chemotherapeutic drugs are often used to prolong life expectancy. However, clinical practice has shown that, due to MDR, GCs are less sensitive to chemotherapeutic drugs than many other cancers. Therefore, for GC cells, identification of upstream mechanisms that regulate MDR and agents that reverse MDR is an emergent issue.

Although stem cell characteristics and transformation of epithelial cells into mesenchymal cells may be responsible for the MDR in GC cells [36], overexpression of membrane transport proteins and apoptosis resistance must be overcome for reversal of the drug resistance of GC cells. Accordingly, a variety of genes and molecules involved in regulation of these two pathways that promote MDR of GC cells, especially protooncogenes and micro-RNAs, have been found. For instance, during apoptosis of GC cells, mutation and deactivation of the tumor suppressor gene p53 enhance DNA repair, reducing adriamycin and 5-fluorouracil based chemosensitivity [37]. Decreases of miR143, miR449, and...
Figure 5: Ubenimex decreases the expression of P-gp and MRP1 by inhibiting CD13 expression to alleviate the activation of PI3K/AKT/mTOR pathway. ((a) and (b)) Indicated cells were pretreated with pEGFP-N1-CD13 plasmid and then stimulated with Ubenimex. Expressions of total and phospho-proteins related to PI3K/AKT pathway in SGC7901/X (a) and MKN45/X (b) cells were identified by western blotting analysis. Data are shown as representatives (left panels) or means (right panels). **P < 0.01 and #P > 0.05. ((c) and (d)) Coimmunoprecipitation of endogenous mTOR and P-gp or MRP1 in indicated MDR GC cells with the treatment of Ubenimex (400 μmol/l) for 24h. Total cell lysates were used as an input control and were subjected to immunoprecipitation and western blotting analysis with the indicated antibodies.

miR503 expression activate antiapoptotic proteins of the Bcl-2 family, promoting resistance towards cisplatin and etoposide [38–40]. miR-508-5p targets the 3’UTR of the zinc finger domain in the transport protein, ABCB1, thereby inhibiting its expression; however, miR-508-5p expression is reduced in SGC7901 cells treated with 5-fluorouracil, oxaliplatin, and doxorubicin [41].

CD13 induces stem cell characteristics and MDR of hepatoma cells, and CD13+ cells in liver cancer transplants show higher proliferation and greater resistance to doxorubicin and 5-fluorouracil than CD13− cells [42, 43]. These findings raise the possibility that in tumor cells CD13 expression regulates MDR. Consistent with this possibility, we demonstrated that CD13 expression was evident in GC tissues, but not in normal controls. Further studies affirmed that CD13 was expressed at higher levels in tissue samples from the GC patients who received chemotherapy. These findings were verified with GC cell lines; CD13 expression in MDR GC cells was higher than that in their parental cells. Moreover, for MDR GC cells, silencing of CD13 expression by the pTZU-CD13-shRNA plasmid reduced IC50 values and RIs. Thus, our results show that, in GC cells, CD13 is associated with MDR. Based on these findings, we confirmed that Ubenimex decreased the IC50 values and RIs for SGC7901/X and MKN45/X cells to chemotherapeutic drugs and enhanced chemosensitivity of MDR GC cells to the FOLFOX regimen, for which ablation of CD13 expression is essential. Based on these results, we consider that, as a chemotherapeutic adjuvant, Ubenimex reverses MDR in GC cells by targeting CD13 and increasing GC sensitivity to chemotherapeutic drugs.
proteins; the latter is involved in inhibition of cell apoptosis [44]. The proapoptotic proteins in the Bcl-2 family promote the release of Cyto-C from mitochondria by altering permeability of the mitochondrial membrane, and IAPs, especially XIAP and survivin, inhibit the release of Smac [30]. Competition between the factors determines if there is activation of a cascade of the caspase family, particularly splicing and maturation of caspase-3 or caspase-8, thereby inducing tumor cell apoptosis [45]. The present studies showed that, by inhibiting CD13 expression in GC cells, Ubenimex promoted FOLFOX-induced apoptotic inhibition in which the expression of apoptosis-related proteins is changed. Notably, expression of anti-apoptotic proteins, including Bcl-2, survivin, and Bcl-xl, was downregulated, but the expression of proapoptotic Bax was upregulated. Furthermore, the release of Cyto-C and protein expression of Smac were induced by Ubenimex. Consequently, there is reason to believe that CD13 decrease mediated by Ubenimex suppressed Bcl-2/Cyto-C and the IAP/Smac pathways to activate the caspase-3-mediated apoptotic cascade, resulting in downregulation of anti-apoptotic proteins and upregulation of a proapoptotic protein; and (iv) Ubenimex inhibits activation of the PI3K/AKT/mTOR pathway to downregulate expression of P-gp and MRP1, a process dependent on the reduction of CD13 expression.

Associated with the drug resistance of GC cells are various signaling pathways, including the PI3K/AKT pathway, the nuclear factor erythroid-2-related factor 2 (Nrf2-ARE), and the Notch signaling pathway [46–48]. Activation of AKT is associated with increased resistance of GC cells towards various chemotherapeutic drugs, including 5-fluorouracil, doxorubicin, mitomycin C, and cisplatin [49]. Moreover, adriamycin stimulates AKT and PI3K activity in a dose- and time-dependent manner to promote chemotherapeutic resistance of GC cells [50]. However, whether activation of the PI3K/AKT pathway upregulates expression of membrane transport proteins to promote drug efflux or is involved in MDR formation of GC cells via other mechanisms is uncertain. Perhaps activation of the PI3K/AKT pathway confers chemotherapeutic resistance that is unrelated to drug efflux in AGS cells (derived from an adenocarcinoma of the stomach) and other GC cells [51]. Expression of P-gp is reduced in SCG7901/doxorubicin cells after application of the PI3K inhibitor LY294002 [52]. In the present study, we demonstrated that, in MDR GC cells, Ubenimex downregulated the expression of membrane transport proteins, including P-gp and MRP1, reducing intracellular efflux and increasing the accumulation of chemotherapeutic drugs. The decrease of MDR-associated proteins was dependent on a reduction of CD13 expression, suggesting that, in GC cells, CD13 is the target by which Ubenimex reverses MDR.

The reduced expression of MDR proteins mediated by Ubenimex was accompanied by decreased activation of the PI3K/AKT pathway, in which the phosphorylation of PI3K and AKT were suppressed. mTOR, but not GSK-3β or JNK, was the tyrosine kinase receptor located downstream of AKT, and, in Ubenimex-treated MDR GC cells, mTOR bound to P-gp and MRP1 proteins. Thus, Ubenimex downregulated the expression of P-gp and MRP1 via inhibiting the PI3K/AKT/mTOR pathway, in which posttranscriptional regulation of proteins could be involved. Consistent with previous reports, our findings support the view that, in GC cells, the PI3K/AKT pathway participates in the formation of MDR by inducing expression of membrane transport proteins.

5. Conclusion

This is the first study to show that (i) CD13 expression is positively associated with MDR formation in GC cells; (ii) Ubenimex reverses MDR and enhances chemosensitivity of SGC7901/X cells to the FOLFOX regimen by inhibiting expression of CD13; (iii) by suppressing CD13 expression, Ubenimex promotes FOLFOX-induced apoptosis upon activation of the caspase-3-mediated apoptotic cascade, resulting in downregulation of anti-apoptotic proteins and upregulation of a proapoptotic protein; and (iv) Ubenimex inhibits activation of the PI3K/AKT/mTOR pathway to downregulate expression of P-gp and MRP1, a process dependent on the reduction of CD13 expression.

These results indicate that Ubenimex is a candidate drug for reversing the MDR of GC cells, providing a new approach to the development of more potent cancer therapy.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This work was supported by the Natural Science Foundation of Shandong Province, China (ZR2017MH045).

Supplementary Materials

The Supplementary Material included three tables entitled Supplementary Table S1, Supplementary Table S2, and Supplementary Table S3. (Supplementary Material)

References

[1] T. L. Ang and K. M. Fock, “Clinical epidemiology of gastric cancer,” Singapore Medical Journal, vol. 55, no. 12, pp. 621–628, 2014.

[2] H. Yoon and N. Kim, “Diagnosis and management of high risk group for gastric cancer,” Gut and Liver, vol. 9, no. 1, pp. 5–17, 2015.

[3] S. Lee and S. C. Oh, “Changing strategies for target therapy in gastric cancer,” World Journal of Gastroenterology, vol. 22, no. 3, pp. 1179–1189, 2016.

[4] V. Brower, “Modified gastric cancer chemotherapy: more effective, less toxic,” The Lancet. Oncology, vol. 16, no. 16, p. e590, 2015.
[5] T. P. Batista, C. A. A. L. de Santos, and G. F. G. Almeida, “Perioperative chemotherapy in locally advanced gastric cancer,” Arquivos de Gastroenterologia, vol. 50, no. 3, pp. 236–242, 2013.

[6] A. Díkgwa and A. D. Wagner, “Advanced gastric cancer: Current treatment landscape and future perspectives,” World Journal of Gastroenterology, vol. 22, no. 8, pp. 2403–2414, 2016.

[7] D. Zhang and D. Fan, “Multidrug resistance in gastric cancer: Recent research advances and ongoing therapeutic challenges,” Expert Review of Anticancer Therapy, vol. 7, no. 10, pp. 1369–1378, 2007.

[8] S. V. Vtorushin, K. Y. Khristenko, and M. V. Zavyalova, “The phenomenon of multi-drug resistance in the treatment of malignant tumors,” Experimental Oncology, vol. 36, no. 3, pp. 144–156, 2014.

[9] D. Florou, C. Patsis, A. Ardavanis, and A. Scorlas, “Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells,” Cancer Biology & Therapy, vol. 14, no. 7, pp. 587–596, 2013.

[10] D. Wang, Y. Sun, F. Ye et al., “Anti-tumor activity of the X-linked inhibitor of apoptosis (XIAP) inhibitor embelin in gastric cancer cells,” Molecular and Cellular Biochemistry, vol. 386, no. 1-2, pp. 143–152, 2014.

[11] J. Silke and D. Vucic, “IAP family of cell death and signaling regulators,” Methods in Enzymology, vol. 545, pp. 35–65, 2014.

[12] W. Shi and J. Gao, “Molecular mechanisms of chemoresistance in gastric cancer,” World Journal of Gastrointestinal Oncology, vol. 8, no. 9, pp. 673–681, 2016.

[13] Z. Chen, T. Shi, L. Zhang et al., “Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade,” Cancer Letters, vol. 370, no. 1, pp. 153–164, 2016.

[14] J. Cui, Y. Yin, Q. Ma et al., “Comprehensive characterization of the genomic alterations in human gastric cancer,” International Journal of Cancer, vol. 137, no. 1, pp. 86–95, 2015.

[15] A. Rocco, D. Compare, E. Liguori et al., “MDRI-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in GC cells,” Laboratory Investigation, vol. 142, no. 5, pp. 1407–1418, 2012.

[16] G. d. Rocha, R. R. Oliveira, M. A. Kaplan, and C. R. Gattass, “β-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity,” European Journal of Pharmacology, vol. 741, no. 1, pp. 140–149, 2014.

[17] W. Hu, C. Peng, and Y. Li, “The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer,” Journal of Experimental & Clinical Cancer Research, vol. 26, no. 1, p. 144, 2009.

[18] H. A. Burris III, “Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway,” Cancer Chemotherapy and Pharmacology, vol. 71, no. 4, pp. 829–842, 2013.

[19] S. Faes and O. Dormond, “PI3K and AKT: Unfaithful partners in cancer,” International Journal of Molecular Sciences, vol. 16, no. 9, pp. 21138–21152, 2015.

[20] Z.-Q. Yuan, R. I. Feldman, G. E. Sussman, D. Coppola, S. V. Nicosia, and J. Q. Cheng, “AKT2 inhibition of cisplatin-induced JNK/p38 and bax activation by phosphorylation of ASK1. Implication of AKT2 in chemoresistance,” The Journal of Biological Chemistry, vol. 278, no. 26, pp. 23432–23440, 2003.

[21] W. Jin, L. Wu, K. Liang, B. Liu, Y. Lu, and Z. Fan, “Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells,” British Journal of Cancer, vol. 89, no. 1, pp. 185–191, 2003.

[22] L. Wang, C. Wang, Y. Jia, Z. Liu, X. Shu, and K. Liu, “Resveratrol increases anti-proliferative activity of bestatin through downregulating p-glycoprotein expression via inhibiting PI3K/Akt/mTOR Pathway in K562/ADR cells,” Journal of Cellular Biochemistry, vol. 117, no. 5, pp. 1233–1239, 2016.

[23] X. Wang, F. Jing, H. Zhu, H. Fang, J. Zhang, and W. Xu, “Activity screening and structure-activity relationship of the hit compounds targeting APN/CD13,” Fundamental & Clinical Pharmacology, vol. 25, no. 2, pp. 217–228, 2011.

[24] P. Mina-Osorio, “The moonlighting enzyme CD13: old and new functions to target,” Trends in Molecular Medicine, vol. 14, no. 8, pp. 361–371, 2008.

[25] M. Wickström, R. Larsson, P. Nygren, and J. Gulbø, “Aminopeptidase N (CD13) as a target for cancer chemotherapy,” Cancer Science, vol. 102, no. 3, pp. 501–508, 2011.

[26] Q. Guo, Z. Sui, W. Xu et al., “Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells,” Oncotarget, vol. 8, no. 42, pp. 72652–72665, 2017.

[27] S. Carl-McGrath, U. Lendeckel, M. Ebert, A.-B. Walter, A. Roessner, and C. Rücken, “The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer,” International Journal of Oncology, vol. 25, no. 5, pp. 1223–1232, 2004.

[28] T. Yamazaki, K. Sugiyama, and K. Ichihara, “Effect of ubenimex on the immune system of patients with hematological malignancies,” Biomedicine & Pharmacotherapy, vol. 45, no. 2-3, pp. 105–112, 1991.

[29] J. Martinezfábregas, I. Diazmoreno, K. Gonzálezarzola et al., “Structural and functional analysis of novel human cytochrome C targets in apoptosis,” Molecular & Cellular Proteomics, vol. 13, no. 6, pp. 1439–1456, 2014.

[30] S. Fulda, “Promises and challenges of Smac mimetics as cancer therapeutics,” Clinical Cancer Research, vol. 21, no. 22, pp. 5030–5036, 2015.

[31] P. Yu, Y. Du, L. Yang et al., “Significance of multidrug resistance gene-related proteins in the postoperative chemotherapy of gastric cancer,” International Journal of Clinical and Experimental Pathology, vol. 7, no. II, pp. 7945–7950, 2014.

[32] C. Hamashima, “Current issues and future perspectives of gastric cancer screening,” World Journal of Gastroenterology, vol. 20, no. 38, pp. 13767–13774, 2014.

[33] N. Chikazawa, H. Tanaka, T. Tasaka et al., “Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells,” Anticancer Research, vol. 30, no. 6, pp. 2041–2048, 2010.

[34] M. P. Kim and G. E. Gallicke, “Gemcitabine resistance in pancreatic cancer: Picking the key players,” Clinical Cancer Research, vol. 14, no. 5, pp. 1284–1285, 2008.

[35] C. Liang, X.-J. Yu, X.-Z. Guo et al., “MicroRNA-33a mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine,” Oncotarget, vol. 6, no. 16, pp. 14440–14455, 2015.

[36] I. Fioroni, E. Dell’Aquila, F. Fantano et al., “Role of epithelial-mesenchymal transition in gastric cancer initiation and progression,” World Journal of Gastroenterology, vol. 16, no. 8, pp. 1195–1207, 2015.

[37] A. I. Zaika, J. Wei, J. M. Noto, R. M. Peek, and J. B. Bliska, “Microbial regulation of p53 tumor suppressor,” PLoS Pathogens, vol. 11, no. 9, p. e1005099, 2015.
[38] M. Zhuang, Q. Shi, X. Zhang et al., “Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2,” *Tumor Biology*, vol. 36, no. 4, pp. 2737–2745, 2015.

[39] J. Hu, Y. Fang, Y. Cao, R. Qin, and Q. Chen, “MiR-449a regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells,” *Digestive Diseases and Sciences*, vol. 59, no. 2, pp. 336–345, 2014.

[40] D. Wu, G. Cao, Z. Huang et al., “Decreased miR-503 expression in gastric cancer is inversely correlated with serum carcinoembryonic antigen and acts as a potential prognostic and diagnostic biomarker,” *OncoTargets and Therapy*, vol. 10, pp. 129–135, 2017.

[41] Y. Shang, Z. Zhang, Z. Liu et al., “MiR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1,” *Oncogene*, vol. 33, no. 25, pp. 3267–3276, 2014.

[42] B. Christ, S. Brückner, and S. Winkler, “The Therapeutic Promise of Mesenchymal Stem Cells for Liver Restoration,” *Trends in Molecular Medicine*, vol. 21, no. 11, pp. 673–686, 2015.

[43] N. B. Vu, T. T. Nguyen, L. C.-D. Tran et al., “Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties,” *Cytotechnology*, vol. 65, no. 4, pp. 491–503, 2013.

[44] M. Hassan, H. Watari, A. AbuAlmaaty, Y. Ohba, and N. Sakuragi, “Apoptosis and molecular targeting therapy in cancer,” *BioMed Research International*, vol. 2014, Article ID 150845, p. 23, 2014.

[45] S. Shalini, L. Dorstyn, S. Dawar, and S. Kumar, "Old, new and emerging functions of caspases," *Cell Death & Differentiation*, vol. 22, no. 4, pp. 526–539, 2015.

[46] Y. Kawasaki, S. Ishigami, T. Ariga et al., “Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer,” *BMC Cancer*, vol. 15, no. 1, 2015.

[47] Y. Yao, Y. Ni, J. Zhang, H. Wang, and S. Shao, “The role of Notch signaling in gastric carcinoma: molecular pathogenesis and novel therapeutic targets,” *Oncotarget*, vol. 8, no. 32, pp. 53839–53853, 2017.

[48] I. Riquelme, O. Tapia, J. A. Espinoza et al., “The gene expression status of the PI3K/AKT/mTOR pathway in gastric cancer tissues and cell lines,” *Pathology & Oncology Research*, vol. 22, no. 4, pp. 797–805, 2016.

[49] J. Liang, F. Ge, C. Guo et al., “Inhibition of PI3K/Akt partially leads to the inhibition of PrP C-induced drug resistance in gastric cancer cells,” *FEBS Journal*, vol. 276, no. 3, pp. 685–694, 2009.

[50] B. Zhang, Y. Yang, X. Shi et al., “Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-ββ-catenin signaling and epithelial–mesenchymal transition,” *Cancer Letters*, vol. 276, no. 3, pp. 704–712, 2015.

[51] K. Mahajan and N. P. Mahajan, “PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics,” *Journal of Cellular Physiology*, vol. 227, no. 9, pp. 3178–3184, 2012.

[52] Z. Han, L. Hong, and Y. Han, “Phospho AKT mediates multidrug resistance of GC cells through regulation of P-gp, Bcl-2 and Bax,” *Journal of Experimental & Clinical Cancer Research*, vol. 26, no. 2, pp. 261–268, 2007.